Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study).

NCT04111978 is registered in ClinicalTrials.gov with Swiss GO Trial Group as lead sponsor.

NCT NCT04111978
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04111978 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer: a Randomized Double-blinded Placebo-controlled Multi-centre Phase III Trial (ENGOT-ov54/Swiss-GO-2/MATAO), Including LOGOS (Low Grade Ovarian Cancer Sub-study).
Lead sponsor
Swiss GO Trial Group
Phase
Phase 3
Overall status
Recruiting
Start date
November 5, 2020
Completion date
July 1, 2032
Enrollment
540 (estimated)
Sites
53

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube neoplasms, high-grade serous ovarian carcinoma (hgsoc), low-grade serous ovarian carcinoma (lgsoc), ovarian endometrioid carcinoma, ovarian neoplasm epithelial, peritoneal neoplasms